Prihlásiť sa Zaregistrujte sa zadarmo

Návratnosť aktív spoločnosti Edesa Biotech

Aká je hodnota metriky Návratnosť aktív spoločnosti Edesa Biotech?

Hodnota metriky Návratnosť aktív spoločnosti Edesa Biotech, Inc. je -97.50%

Aká je definícia metriky Návratnosť aktív?



Návratnosť aktív (Return on assets - ROA) je rentabilita aktív. Vypočíta sa vydelením celkového príjmu priemerom celkových aktív.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Návratnosť aktív spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Edesa Biotech

Čomu sa venuje spoločnosť Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy s metrikou návratnosť aktív podobnou spoločnosti Edesa Biotech